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Development and implementation of technology downtime simulations at 
Baystate Medical Center 
A. Rock; A. Pesaturo; S. Illig; Baystate Medical Center, Springfield, MA 
BACKGROUND 
Limitations 
• Number of staff trained and assessed (small numbers for analysis) 
• Training causes interruptions in workflow 
• Difficulty in capturing entire staff 
 
Future Implications 
• Downtime protocols should be implemented for all complex technology.  
• The initial mock simulation based training of these protocols should occur 
during pharmacist and pharmacy technician training/orientation.  
• Periodic planned mock simulations should be planned and additional staff 
scheduled to prevent workflow interruptions should be provided to 







A gap analysis was performed to identify areas with and without downtime 
protocols in place. BD Pyxis™ Logistics Carousel was identified as an area 
without comprehensive downtime standard operating procedures.  
 
8 – Point Assessment  
Describe  
• Where to find resources, to help triage carousel down time problems. 
Explain  
• How to forward labels from this carousel printer A to carousel printer B or C. 
• What order you would begin to manually enter a batch fill in the event of an extended time 
without the batch fill dropping? 
• How many hours would you wait till manually entering the fill? 
Identify  
• Who to contact and in what order for a mechanical obstruction.  
• Where the carousel drill, clamp, downtime binder and paper inventory are.  
• Where replacement batteries are for the scanners, and explain how to reset them.  
• Where the key is to open drill access panel. 
Demonstrate   
• How to open drill access panel, and explain how the drill is attached and functions. 
 
CONCLUSIONS 
• Simulated based training increases response rates and 
accuracy in response 
 
• The results of this project could be extrapolated to other 
complex technology or operational systems 
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Research Question: Do mock 
simulation based trainings in 
addition to creation of new 
protocols increase the self-
sufficiency of frontline pharmacy 
staff during downtime events more 
so than new protocols alone? 
 
    
Technical Downtime 
1. ADM : Carousel Interface  
2. BD™ Logistics* Ordering Software Interface 
3. Scanners 
4. Printers 
5. Batch fills not printing  
6. Carousel PC error  
Mechanical Downtime 
1. Obstruction 
2. Motor/Electric  
Advancing hospital technology 
Improvements in safety and patient care 
Reliance on technology for daily workflow 
Technology 
Inconsistent response to downtime 
events 
Delays in care 
Increased dispensing errors 
Training  Score Before Score After Total Score  
1 0 8 8 
2 0 8 8 
3 1 8 8 
4 0 8 8 
5 0 8 8 
6 0 8 8 
7 3 8 8 
8 3 8 8 
9 2 8 8 
10 1 8 8 
Average 1 8 8 
No Training Score After Total Score  Time (m) 
1 4 8 20 
2 6 8 12.5 
3 7 8 13.5 
Average:  5.67 8.00 15.33 
% Successful:  70.83     
Training Score After Total Score  Time (m) 
1 8 8 6 
2 8 8 5.5 
Average:  8 8 5.75 
% Successful:  100     
% Increase in Score 41.18 % Faster Response 66.67 
Table 1: Scores before and after initial training  
Table 2: Reassessment scores and analysis of training  
Figure 1: Flow diagram of methods 
Figure 2: Areas of potential carousel downtime  and format of  simulation 
Thirty Minute Simulation:  
1. Orient staff to the protocol  
2. Simulate 
• Forwarding labels 
• Running automated dispensing 
machine (ADM) inventory 
report 
• Resetting scanners 
• Opening carousel drill panel 
• Attaching carousel drill 
• Finding the emergency order 
RESULTS 
RESULTS 
With the continued rise in pharmaceutical drug costs, 
stabilizing pharmacy spend with cost-containment 
initiatives remain a strategic focus.  
 Pharmacy leaders are guiding collaborative efforts to 
buy, manage, and use medications as cost-effectively 
as possible1 
  Clinical pharmacy services are able to provide an 
important foundation for a successful high-cost 
medication-utilization management program2 
 Baystate Medical Center (BMC) participates in the 
340B Program as well as group purchasing 
organizations (GPO) 
 
Three of the top ten drug expenses at BMC are 
hemostatic agents 
 
 Hemostatic agents available at BMC through a 
consignment program: 
• Advate® (recombinant factor VIII) 
• Bebulin® (3 factor prothrombin complex concentrate) 
• Benefix® (recombinant factor IX) 
• FEIBA® (activated prothrombin complex concentrate) 
• Humate-P® (vWF and factor VIII) 
• Kcentra® (4 factor prothrombin complex concentrate) 
• NovoSeven® (recombinant activated factor VII) 
 Understanding the workflow of high cost medications, 





B A C K G R O U N D  O B J E C T I V E S  
 Identify and address areas of improvement in the 
process of drug procurement through administration 
and charging for hemostatic agents 
O U T C O M E S  D I S C U S S I O N  
 Repeat gap analysis for hemostatic agents in 6 
months to assess compliance with SOP  
 Consider implementing additional drugs into the high-
cost medication SOP  
 
F U T U R E  C O N S I D E R A T I O N S  
R E F E R E N C E S  
D I S C L O S U R E  
Authors of this presentation have nothing to disclose concerning possible 
financial or personal relationships with commercial entities that may have a 
direct or indirect interest in the subject matter of this presentation  
1. Maximizing pharmacy performance. Vizient. Web site. Available at: 
https://www.vizientinc.com//media/Documents/SitecorePublishingDo
cuments/Public/MaxPharmPerfWhirePaper.pdf. Accessed September 
18, 2018. 
2. American Society of Health-System Pharmacists. ASHP guidelines on 
medication cost management strategies for hospitals and health 
systems. Am J Health-Syst Pharm. 2008; 65:1368–84. 
3. Humate P. Canada: CSL Behring. 2018. https://ww.humate-
p.com/Professional/About-Humate-P/Default.aspx. Accessed 
November 17, 2018. 
4. FEIBA. Westlake Village, CA: Baxter Healthcare Corporation. 2005. 
http://www.baxter.com.pr/patients_and_caregivers/products/feiba_v
h.html 
M E T H O D S  
Development of a cost containment strategy for high-cost medications 
at a tertiary teaching hospital 
Kelly Nguyen, Pharm.D.; John Stiles, Pharm.D.; Kathleen Kopcza, Pharm.D., BCPS;  
Erica Housman, Pharm.D., BCPS (AQ-ID) 
Contact Information: 
Kelly Nguyen, Pharm.D.  
PGY1 Pharmacy Resident 
Kelly.Nguyen@BaystateHealth.org 
Interests: Cardiology 
 A gap analysis was created and performed to identify 








     
      
 Date range: Retrospective chart review of historical 
order data 
• Humate P®: Sep. 2016 - Oct. 2018 
• FEIBA®: Jun. 2016 - Jul. 2018 




 Lost charges from high-cost medications, such as 
hemostatic agents, can be costly to the department 
and institution 
 Lack of awareness of clear criteria for ordering, 
verifying  and dispensing hemostatic agents increases 
risk for medication errors 
 Cost-containment can be complex and requires high-
level strategic planning and extensive collaboration  
 Successful drug cost management requires 
systematic attention to and integration of both 
clinical and operational approaches 
 Total financial opportunity over 2 years= $408,533 
• Cost savings using 340B:  $24,655  





 Initial target medications:   
                  Humate P®                             FEIBA® 
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Purchasing 





Charting on MAR 
Continued 
assessment of need 
• Least amount of drugs purchased 
from wholesale acquisition (WAC) 
account 
• Drugs purchased from 340B in 
340B eligible patients 
Purchasing 
• Proper stock available on shelves 
• Expiration dating done correctly Stock/Storage 
• Restrictions/ criteria for   
initiation 






• Pharmacist aware of patients on 
the high-cost medications to 




Appropriate Use  
• Charted on the medical 
administration record (MAR) 
• Amount of medications 
charged=amount of medications 
re-purchased 
Charging 
 Gap analysis results: Humate P®   n=20 patients  














 Areas of improvement identified: 
 
Purchasing 





Charting on MAR 
Continued 
assessment of need 
Inconsistent 
response to alert 
by pharmacists. No 
standardized 
protocol. 
50% Humate P®, 56% FEIBA® 
patients had orders given in 
outpatient setting 
Humate P®: 85% 
FEIBA®: 81% 
 patients with 
hematology 
consult 
Inconsistent documentation and dispensing 
15% Humate 
P®,  
31% FEIBA®  
patients with at 
least 1  missed 











for  determining 
appropriate 
continuation 
1. Lack of awareness of predefined criteria related to ordering, 
verifying, and dispensing 
• Standard operating procedure (SOP) created to address order entry, verification, and 
dispensing of hemostatic agents available on the BMC formulary 
• SOP introduced to the pharmacy department through the Clinical Leadership Team 
• SOP will be posted on the department’s internal webpage 
• An attestation form will be sent to all pharmacists  
2. Lack of a standardized process for documenting hemostatic 
agents dispensed 
• SOP includes: 
• New dose-rounding policy: Doses may be rounded DOWN or UP to the next appropriate dose 
and/or vial size by the pharmacist as a protocol order if the dose is ≤ 10%  
• Nearest nominal vial size 
• Standardized proper documentation of hemostatic agents in the CPOE system (computerized 
physician order entry) 
3. Unclear expectations for continued monitoring by clinical 
pharmacists 
• High-Cost Medication Alert  
• SOP describes expectations for clinical pharmacists to evaluate the need for continuation of 
the medication 
• Ensure hematology consultation for continued use 
4. Inaccurate medication charting, resulting in lost charges and 
increased risk for medication errors 
• New real-time High-Cost Medication Hemostatic Agent Alert via email built for pharmacy 
purchasing team members 
• Evaluation of proper documentation in the MAR 
5. Decision between cost-containment strategies: Consignment 
vs 340B 
• Humate P® cost difference: $0.14/unit 
• $0.14/unit x 39,000 outpatient units = $5,460 (Sep. 2016 - Oct. 2018) 
• FEIBA® cost difference: $0.65/unit 
• $0.65/unit x 29,500 outpatient units = $19,195 (Jun. 2016 - Jul. 2018) 
Evaluation of AUC-based Vancomycin Dosing Practices in Patients with 
Bloodstream Infections Caused by Methicillin-Resistant Staphylococcus aureus  
Rebecca R. Marcinak, PharmD1; Seth T. Housman, PharmD, MPA1,2; Lydia J. D’Agostino, PharmD, BCPS1;  
Erica L. Housman, PharmD, BCPS (AQ-ID)1 
1. Baystate Medical Center; 2. Western New England University CoPHS  ─  Springfield, Massachusetts 
 Vancomycin is often considered the drug of choice for serious methicillin-
resistant Staphylococcus aureus (MRSA) infections, including bacteremias.  
 Area under the curve/minimum inhibitory concentration (AUC/MIC) ratio is the 
pharmacodynamic parameter best associated with vancomycin's effectiveness 
in treating such infections. 
 Current guidelines advocate for an AUC/MIC target of at least 400 to achieve 
optimal bactericidal effect against S. aureus. 
 High trough levels have been associated with an increased risk of 
nephrotoxicity.  
 Recent literature suggests: 
 Single trough levels offer little prediction of the AUC. 
 The goal AUC/MIC of >400 can be achieved with trough levels much lower 
than the recommended 15-20 mg/L. 
  At Baystate Medical Center (BMC), vancomycin AUC-based monitoring is 
performed for patients with identified MRSA bacteremia.  
 On initiation of therapy, empiric AUC calculations are performed using 
population-based kinetics. 
 Once the patient is at steady state, a peak and trough level are obtained 
and patient-specific AUC is calculated. 
B A C K G R O U N D  
M E T H O D S  
R E S U L T S  
O B J E C T I V E S  
•Correlation between empiric AUC calculations and patient-
specific AUCs Primary: 
•Percent of patients who met the AUC goal of ≥400 mg/L•hr-1  
•Mean initial trough concentration in those that met goal 
versus those that did not 
Secondary: 
y = 0.2279x + 364.91 






















Predicted AUC (mg/L•hr-1)  
Cmin <10 mg/L 5 (36) 
Cmin 10-14.9 mg/L 16 (84) 
Cmin 15-19.9 mg/L 7 (100) 
Cmin ≥20 mg/L 2 (100) 
Patients who met AUC Goal Stratified by Initial 
Trough Concentration; N (%) 
 All adult patients with bloodstream infections caused by MRSA treated with 
AUC-based vancomycin regimens from Jan 2018 to Feb 2019 were reviewed.   
 Exclusion criteria:  
 Pregnant 
 Receipt of renal-replacement therapy while on vancomycin  
 Lack of two steady-state vancomycin concentrations  
 Institutional review board approval was granted prior to data collection. 
 Empiric vancomycin AUC and pharmacokinetic data, as calculated via 
Vancomycin Initial Dosing Calculator on vancopk.com, were collected. 
 Patient-specific AUC and pharmacokinetic data were calculated using the 
trapezoidal equation-based approach. 
 Vancomycin MICs were assumed to be 1 mg/L. 
AUC Distribution following Empiric Calculations;  
N (%) 
76 adult patients treated 
with vancomycin for MRSA 
bacteremia 
Patients Excluded: 
• Pregnant: 3 
• Received renal-
replacement therapy: 9 
• Did not have two levels 
collected: 22 
42 patients included for 
review 







Source of Infection: 
• Skin and soft tissue 
• Endovascular 
• Intravenous catheter 














Mean (± SD) 
Age (yr) 
Height (cm) 
Total body weight (kg) 
Ideal body weight (kg) 
Adjusted body weight (kg) 
CrCl† (mL/min) 
Total Daily Dose‡ (mg/kg) 
56 (± 20) 
171.5 (± 10.2) 
76.2 (± 18.6) 
65.6 (± 11.3) 
69.3 (± 12.2) 
103 (± 54.4) 










*CKD, chronic kidney disease; **IVDU, 
intravenous drug use; †CrCl, creatinine 
clearance (Cockcroft-Gault); ‡based on total 
body weight 
D I S C U S S I O N  
 Empiric AUC calculations through population-based kinetics did not produce a strong correlation to patient-specific AUCs.  
 Regardless, following the AUC-based empiric dosing strategy, most patients met the AUC goal of ≥400 mg/L•hr-1.  
 These findings are consistent with prior data that suggest the AUC goal of ≥400 mg/L•hr-1 can be attained in most patients that 
achieve a vancomycin trough concentration of ≥10 mg/L. 
Comparison of Population-Based vs. Calculated AUC 
Significant difference in the mean initial trough concentration in patients 
who met the AUC goal vs. those who did not  




















Limitations Future Directions  
Small sample size, inability to assess patient outcomes  Continue to collect data to increase sample size 
Data regarding the use of concomitant nephrotoxic agents and 
attainment of source control were not collected  
Assess patient-specific factors that may account for differences in 
predicted vs. observed AUCs 
MICs were assumed to be 1 mg/L 
References:  
1. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients : A consensus review of the American Society of Health-System 
Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66:82-98. 
2. Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. 
Antimicrob Agents Chemother. 2018;62(2):e02042-17. 
3. Hale CM, Seabury RW, Steele JM, et al. Are vancomycin trough concentrations of 15 to 20 mg/L associated with increased attainment of an AUC/MIC ≥ 400 in patients 
with presumed MRSA infection? J Pharm Pract. 2017;30(3):329-335. 
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Identifying discrepancies within the discharge summary in the  
Acute Care for the Elderly (ACE) Unit  
Kelly Sawyer, PharmD; Megan Carr, PharmD, BCPS, BCGP; Erica Housman, PharmD, BCPS (AQ-ID); Shawn Roggie, PharmD, MBA 
INTRODUCTION 
It is estimated that approximately 29% of American adults take five 




Identify the prevalence of medication discrepancies within discharge 
medication notes  for patients located on the Acute Care for the Elderly Unit 
Secondary Objective: 
• Determine whether or not the implementation of a pilot project for 
pharmacist-led service is warranted to review medication lists prior to 
discharge 
• Identify which patient populations may benefit from a pharmacist-led 
discharge service 
It is estimated that pproximately 29%1 of American adults t ke five 
dications or more.  
At our institution, a pharmacist has been incorporated into the Acute Care 
for the Elderly (ACE) Unit since July of 2018.  
• ACE is an evidence-based model of care with the goal to minimize stress 
and prevent functional decline in older adults (≥ 65 years) during 
hospitalization. 
• There is currently no standardized process for pharmacist-review of 
discharge medications at our institution, yet studies have demonstrated 
reduced errors when pharmacists are involved in the medication 
reconciliation process.3  
 
 
The physical discharge medication list was compared to the provider notes 
within the discharge summary to identify discrepancies. 
1. Slone Epidemiology Center at Boston University. Patterns of medication use in the United States, 2006. 
https://www.bu.edu/slone/files/2012/11/SloneSurveyReport2006.pdf. Accessed October 16, 2018. 
2. Cornish PL, Knowles SR, Marchesano R, et al. Unintended medication discrepancies at the time of hospital 
admissions. Arch Intern Med. 2005; 165(4):424-429. 
3. Mekonnen AB, McLachlan AJ, Brien JE. Pharmacy-led medication reconciliation programmes at hospital 





Kelly Sawyer, PharmD 








   Number of discrepancies per patient 
• Therapeutic classes involved in discrepancies 
• Frequency of discrepancy types 
• Stratification of prevalence by subgroup: 
o Number of discharge medications 
oMedication reconciliation status 
o Chronological Age 
      Admitted to and discharged from the ACE unit 
      Chronological Age < 60 years 
METHODS 
Statistics: 
Discrepancies Per Patient: # of discrepancies (total) / # of patients (total) 
Discrepancies Incidence: # patients with discrepancies / # patients in group 
Discrepancy Ratio: # discrepancies in group / # patients with discrepancies in group 
 
Data Collection Period:  January 2019 to March 2019 
 RESULTS 
Primary Outcome Results:  
Secondary Outcome Results:  
STEP 1: 
• This research has identified that our current discharge reconciliation process 
is insufficient at preventing discrepancies and potential medication errors 
STEP 2: 
• Design and implement a pharmacy-led initiative to review medication lists 
prior to discharge within the ACE Unit 
STEP 3: 
• Collect post-intervention data to assess impact and consider implementation 
on a larger scale. 
Discharge Medication Reconciliation: 
Top Therapeutic Classes Involved  
Respiratory Tract Agents (15%) 
Anti-infective Agents (13%) 
Gastrointestinal Agents (11%) 
Opioid Analgesics (9%) 
Antidiabetic Agents (9%) 
Antihypertensive Agents (9%) 
Impact of antibiotic review during transition  
from hospital to community 
Anna Morien, PharmD1; Erica Housman, PharmD, BCPS (AQ-ID) 1; Seth Housman, PharmD, MPA1,2;  
Lydia D’Agostino, PharmD, BCPS1 
1. Baystate Medical Center, Springfield, MA ; 2. Western New England College of Pharmacy and Health Sciences, Springfield, MA 
 Antimicrobial stewardship (AMS) programs have 
largely focused on inpatient care 
 The transition from hospital to community may be 
another opportunity for AMS services when antibiotic 
regimens need to be completed in the outpatient 
setting 
 According to the Center for Disease Control (CDC), 
about 30% of antibiotics prescribed in both inpatient 
and outpatient settings are unnecessary or prescribed 
incorrectly1 
 Inappropriate antibiotic use leads to antimicrobial 
resistance, adverse drug effects, and increased costs 
 Several retrospective studies that assessed antibiotic 
review on hospital discharge have shown that up to 
70% of antibiotics are prescribed inappropriately2 
 In an additional study, 70% of  pharmacist 
recommendations were accepted, and prevented 
potential errors in 68% of patients3 
 Common errors  include duration, dose, and choice of 
antibiotics 
 There is a need to extend  AMS services  beyond the 
inpatient setting to help bridge this gap in care 
 
B A C K G R O U N D  
O B J E C T I V E  
Clinical Impact: 
AMS pharmacists can have a positive impact on the 
transitions of care (TOC) process as seen by the 71.4% 
intervention acceptance rate 
Future Directions: 
 Continuation of AMS TOC interventions as time 
permits 
• Potential role for care team pharmacists outside of 
AMS team to have an impact in this initiative with 
appropriate training 
Develop better strategy to identify patients 
Continue to offer PGY2 ID TOC elective rotation 
 
P R I M A R Y  E N D P O I N T  
L I M I T A T I O N S  
 Single medical unit in single institution  
 Sustainability  
• AMS pharmacists have many other tasks 
throughout the day 
• Time frame from discharge ordered to patient 
being discharged is variable 
 Weekend and evening discharges 
 Discharge unit open January and February 
M E T H O D S  
 Single center, retrospective,  quality improvement 
initiative 
 Interventional group: January 2019 – February 2019 
 Historical control: January 2018 – February 2018 
 Inclusion criteria: 
 Patients at least 18 years of age 
 Admitted to general medicine floor 
 Plan for continuation of antibiotic after 
discharge 
 To evaluate the impact of antimicrobial stewardship 
review of antibiotic prescriptions upon transitions of 
care from hospital to community 
 
I N T E R V E N T I O N  
The pharmacist will make any interventions 
pertaining to the antibiotic when necessary (i.e., 
choice, dose, duration), prior to patient discharge 
The pharmacist will review the patients and 
assess for antimicrobials being prescribed 
at discharge 
AMS team to utilize discharge tracking 
board to identify patients potentially being 
discharged in the next 24-48 hours 
D E M O G R A P H I C S  
Pre-intervention  
Group 
 (Jan-Feb 2018) 
Post-intervention 
Group   























•Number of days of antibiotic 
therapy prescribed upon hospital 
discharge Secondary Endpoints: 
•Number of interventions made 
•Type of intervention made 
•Intervention acceptance rate 
•Any 30-day readmission 
D I S C U S S I O N  
R E F E R E N C E S  
1. Centers for Disease Control and Prevention. Antibiotic use in the United States, 2017: 
progress and opportunities. April 6, 2018. https://www.cdc.gov/antibiotic-use/stewardship-
report/index.html 
2. Scarpato, Sarah J., et al. "An evaluation of antibiotic prescribing practices upon hospital 
discharge." infection control & hospital epidemiology 38.3 (2017): 353-355. 
3. Su, Christy P., et al. "Use of an Anti-Infective Medication Review Process at Hospital Discharge 
to Identify Medication Errors and Optimize Therapy." Journal of pharmacy practice(2018): 
0897190018761411. 
Disclosure:  Authors of this presentation have nothing to disclose concerning possible financial or 
personal relationships with commercial entities that may have a direct or indirect interest in the 
subject matter of this presentation.  
2018 Days of Outpatient 
Therapy 















S E C O N D A R Y  E N D P O I N T S  
Type of Intervention Frequency 
Change in Duration 8  
(25 total DOT avoided) 
Change in Frequency 3 
Antibiotics not Indicated/ 
Completed Therapy 
2 
De-escalation of Therapy 1 
Any 30-day  
Re-admission 
Pre-intervention  





15% (n=15) 20% (n=22) 
 Infection-related   
Re-admission 




1 severe diarrhea, 
C. difficile 
negative 
1 patient possible 
allergic reaction 
to cephalexin  
 14 interventions were made on 11 patients 
 Intervention acceptance rate: 71.4% 
 3 interventions were not accepted due to patient 
already being discharged 
Antimicrobial Class 
Oseltamivir 36 25 
Fluoroquinolones 18 18 
Penicillins  15 22 
Cephalosporins 15 7 
Type of Infection Pre-intervention Post-intervention 
Influenza 36 25 
Pneumonia 16 22 
UTI 10 18 
Ba teremia 11 13 
 Top 4 most frequent indications for antibiotics and top 
4 most frequently prescribed outpatient 
antimicrobials 
BACKGROUND 
Based on studies looking at emergency department (ED) prescription 
noncompliance, the need for a transitions of care (TOC) pharmacist 
within this specialized area has been identified as a means to help 
address gaps in medication therapy and patient knowledge. The 
results are as follows: 
• New medications are prescribed for 2 out of every 3 patients 
discharged from the ED. 
• Up to 35% of patients are noncompliant with their ED discharge 
medications. 
• Medication noncompliance has been shown to be the major 




Addition of the TOC pharmacy resident to the patient care team 
within the fast track area of the ED lead to: 
• Increased access to care 
• Increased medication compliance 




Implementation of Pharmacist Driven Transitions of Care Services in the 
Emergency Department 
Geena Eglin, PharmD1;  Jared Ostroff,  PharmD, BCACP1,2, BCGP; Melanie Conboy PharmD1;  
Derek Charron, PharmD1; Kevin Miller RPh1 
1. Baystate Medical Center; 2. Western New England University CoPHS – Springfield, Massachusetts 
OBJECTIVES 
• Implement a standard process for transitions of care 
services, by a pharmacist, for patients who are 
discharged home 
Primary Objective: 
• Track patient compliance to discharge prescriptions 
from the ED 
• Assess the rate at which patients revisit fast track  
Secondary Objective: 
• The pharmacy resident, working as the TOC pharmacist, joined the 
fast track team consisting of doctors, midlevel practitioners, nurses, 
patient care technicians and scribes. 
• The resident spent one day per week in fast track for 6 weeks; 
Monday was identified as the day with the highest patient census. 
 
Inclusion Criteria 
• Patients seen in fast track and pharmacist consulted for TOC 
services 
• English and non-English speaking patients 
Exclusion Criteria 
• Patients seen in fast track without TOC pharmacist intervention 
• Patients seen outside of fast track 
RESULTS 
Pharmacist Interventions  
• Lack of PCP; RX refill/request 
• Employee needle stick 
• New anticoagulant; financial assistance  
Access & 
Insurance 
• Device training 
• Disease state counseling 
• Adherence counseling 
Education & 
Counseling 
• Medication selection 
• Prescription directions; drug-drug interactions 




Access & Insurance n = 23 (44%) 
Education & Counseling n = 40 (77%) 
Pharmacists Clinical Interventions n = 46 (90%) 
Medication Reconciliation n = 55 (100%) 
• The TOC pharmacist spent a total of 37 hours in fast track 
• During this time, 138 patients were seen by the fast track team 
• 55 patients (40%) out of these total patients received an 
intervention by the TOC pharmacist 
Authors of this presentation have nothing to disclose concerning possible 
financial or personal relationships with commercial entities that may 
have direct or indirect interest in the subject matter of this presentation. 
Fast track prescriptions (n = 55) 
• Baystate Pharmacy compliance: 100% (n = 26) 
• Outside pharmacy compliance: 76% (n = 22) 
• Overall compliance: 87% (n = 48) 
 
30-Day fast track revisit rate = 18% (n = 10) 
• Return for prescription refill = 2 patients  
  












Access & Insurance Interventions 














Education & Counseling 
Interventions (n = 40) 
Limitations Future Implications 
High patient turnover Application of TOC services in the ED 
Single pharmacist operation Expand TOC services in fast track 
Medical team rotation Retail ED dispensing pharmacy  
Sustainability of TOC services Mandated d/c prescription review 
Non-Cognitive Predictors of Student Success: 
A Predictive Validity Comparison Between Domestic and International Students 
Non-Cognitive Predictors of Student Success: 
A Predictive Validity Comparison Between Domestic and International Students 
INTRODUCTION 
• Pain, agitat ion, and delirium (PAD) stewardship 
could be considered a coordinated program aimed 
at promoting evidence-based prescribing of 
opioids and sedat ives 
• Crit ical care pharmacists in a stewardship-type 
role can opt imize an appropriate level of sedat ion 
and pain control in crit ically ill pat ients 
• Retrospect ive evaluat ion of pat ients admit ted to 














Primary  Endpoint : to study the impact  of the 
pharmacist’s intervention on DOT/1000 Pat ient  Days  
and unique administrat ion of opioids and sedat ives in 
mechanically intubated pat ients 
 
• Development  of an inst itut ional pract ice guidelines 






















Pharmacist-driven Implementation of Guidelines for Management 
of Pain, Sedation, and Delirium in a Medical Intensive Care Unit 
Mehrnaz Sadrolashrafi, PharmD; Hannah Spinner, PharmD, BCCCP; Adam Pesaturo, PharmD, BCPS, BCCCP 
 
Characterist ics 
Pre intervent ion  
(n=217) 
Post  intervent ion  
(n=66) 
Age, yr, mean ± SD 62 ± 15  64 ± 15 
Male n (%) 112 (52) 41 (62) 















Indicat ion for mechanical vent ilat ion, n (%) 
Alcohol/drug overdose 
Cardiac Arrest /PEA  
CHF/pulmonary edema 
COPD/asthma 
Gastrointest inal bleed 

























Pre intervent ion  
(n=217) 
Post  intervent ion  
(n=66) 
Length of mechanical intubat ion, 
hr, median, (IQR)  
36 (12-113) 43 (23-104) 
Length of ICU stay,  
hr, median, (IQR) 
64 (30 – 136) 81 (47 – 131) 
DISCUSSION 
• Daily interventions by a crit ical care pharmacy resident  
who implemented the inst itut ional PADIS guideline led 
to a 50% reduction in the number of unique doses of 
fentanyl administered over the durat ion of this study 
 
Future Direct ions 
• Complete the second phase of the study until May 2019 
and conduct  the secondary data analysis  
• Addit ion of the management of PADIS to an onboarding 
training for all incoming PGY1 and PGY2 residents in 
order to offer this service 7 days a week 
• Expand this pract ice guideline to other ICUs within the 








































RASS Score Dist ribut ion  
Pre Intervention
  Pharmacist  Intervent ion (n = 83) n (%) 
  Discont inue opioid cont inuous infusion 16 (20) 
  Decrease infusion rate of opioid 1 (1) 
  Add intermit tent  opioid bolus 22 (27) 
  Add as needed adjunct  non-opioid agent   for pain 8 (10) 
  Start  cont inuous infusion of opioid 9 (11) 
  Discont inue sedat ive agent  10 (12) 
  Decrease infusion rate of sedat ive 5 (6) 
  Add sedat ive agent  3 (4) 
  New init iat ion/dose t it rat ion of typical/atypical ant ipsychot ic 4 (5) 
  Discont inue ant ipsychot ic 4 (5) 
  
Pre intervent ion  
(n=217) 
Post  intervent ion  
(n=66) 
Pat ients with recorded CAM-ICU 
posit ive n (%) 








































Dexmedetomidine Dose Dist ribut ion  
Post
Intervent…
 Dose  Pre intervent ion  Post  intervent ion  
Dexmedetomidine (mcg/kg/hr), 
Mean ±SD, Median  
0.75 ± 0.4 
0.7 























Propofol Dose Distribution  
Post
Interven
 Dose  Pre intervent ion  Post  intervent ion  
Propofol (mcg/kg/min) Mean ±SD, 
Median  
25 ± 16 
20 



























Individual Pat ients  
Dist ribut ion of CPOT >2 Per Intubated 
Pat ients (n=66)  






































Mar-18 Apr-18 May-18 Mar-19
Unique Administrations 188.68 198.87 195.17 222.21
DOT/1000 Patient Days 2696 2599 2718 3008
Dexmedetomidine  





































Mar-18 Apr-18 May-18 Mar-19
Unique Administrations 218.87 195.12 193.31 175.5
DOT/1000 Patient Days 2763 2437 2510 2233
Propofol 





































Mar-18 Apr-18 May-18 Mar-19
Unique Administrations 369.81 371.48 397.77 352.83
DOT/1000 Patient Days 3497 4000 4002 2001
Fentanyl 
  
Pre intervent ion  
(n=217) 
Post  intervent ion  
(n=66) 
Haloperidol n (%) 
Quet iapine n (%) 







DOT/1000 Pat ient  Days  
Unique Administ rat ions  
DOT/1000 Pat ient  Days  
Unique Administ rat ions  
DOT/1000 Pat ient  Days  
Unique Administ rat ions  
Pharmacists Defining High-Risk Opioid Use Patient 
 Populations at Baystate Medical Center 
 Catherine Chatowsky, PharmD; Melanie Conboy, PharmD;  
Evan Horton PharmD, BCPPS; Shawn Roggie, PharmD, MBA 
 2016: MA ↑ Drug Overdose Death Rate   
Driven by heroin and synthetic opioids  
Deaths: 23.5 per 100,000 population 
2017: 24.5 per 100,000 (4.3% change) 
 
 BMC Pharmacy New FTE Approved 
Pain Management Pharmacist 
Anticipated to start September 2019 
 
 CDC Guidelines: Prescribing Opioids for Chronic Pain  
Clinicians should avoid increasing dosage, or carefully 
justify a decision to titrate dosage, to ≥90 Morphine 
Milligram Equivalents (MME/day) 
High Risk: May increase risk for overdose 
B A C K G R O U N D  R E S U L T S  
O B J E C T I V E S  
D I S C U S S I O N  
Disclosures:  Authors of this presentation have nothing to disclose.  
Define BMC’s High-Risk Opioid-
Using Patient Population: 
BMC IRB Approval to Develop a 
Data Extraction Tool    
Identify areas for BMC Pharmacy 
Pain Management Interventions 
P A T I E N T  S E L E C T I O N  
50 Adult Inpatients 
Eligibility:  
•Adult inpatients administered opioids ≥ 90 MME/day 
Exclusion Criteria:  
•PCA pumps or continuous infusions 
•ED or any ICU patients per day 
•Cancer diagnosis 
•Comfort Measures Only (CMO) Status 
M E T H O D S  












Admission: Hospital Location  Pre-Admission Prescription History 
For ≥ 3 Months Number of patients (%) 
Opioid 18 (36) 
In the Past 3 Months Number of patients (%) 
Benzodiazepine  9 (18) 
Gabapentin or Pregabalin  12 (24) 
Muscle Relaxant  6 (12) 
In the Past 1 Year Number of patients (%) 







First 24 Hours 120 0 960 
Highest 24 Hours 178 95 960 
Discharge Prescription 96 0 663 





Benzodiazepine  20 (40) 9 (18) 
Gabapentinoids 16 (32) 12 (24) 
Muscle Relaxants  7 (14) 6 (12) 





Number of Patients 
66% of Patients had Discharge Prescription(s) ≥ 90 MME/Day  
8% of Patients Discharged without Opioid Prescription(s) 
 Identifying high-risk opioid users is difficult with the current electronic system and data extraction tool. This tool will need to be adapted and refined in the near future. 
  An essential responsibility of the new pain management pharmacist will be to identify high-risk opioid using patients during periods of transitions of care to enhance pain care plans.  
 Identify 50 high-risk opioid using 
patients using data extraction tool    
Check tool daily for eligible patients 
Check eMAR to determine 
administration of ≥ 90 MME/Day 
Recheck patients the next day 
 
 Retrospective Chart Review:  
    50 Patients ≥ 90 MME/Day 
Baseline Characteristics (age, sex) 
Prior opioid use + selected medications 
Diagnosis or history of substance abuse 
Pain + primary discharge diagnosis 
MME/Day: first 24 hrs, admission high, 
discharge 
Inpatient selected medications 




Limitations Future Directions  
Data extraction tool cannot detect drug administrations or MME/Day Build a BMC Opioid Calculator: MME/Day  
No BMC Opioid Calculator: MME/Day Add a rule for opioid-use + benzodiazepines 
May not be capturing all patients on the eMAR.  
 Operating rooms use different eMAR.  
Focus on surgical inpatient floors 
 Evaluate surgical power-plans that allow for high MME/Day 
Identification of opioid dependence is dependent on medical coding Increase awareness and access to naloxone at discharge  





Morphine ≥90 ≥30 







Rules for Data Extraction Tool  
References: 1.) MMWR Morb Mortal Wkly Rep. 2018;67:349–358. 2.) MMWR Morb Mortal Wkly Rep. 2019;67:1419–1427. 3.) MMWR Recomm Rep. 2016;65:1–49. 
n = 75               
                             Age, mean years ± SD 61.6 ± 13.7 
                             Sex 
                                 Male 




                             A1C 
                                 < 7.0 
                                 7.0 – 9.9 





Pharmacy Services at Baystate High Street Health Center 
 
Melanie Conboy, PharmD, Geena Eglin, PharmD, Jennifer Glisson, PharmD, 
Carmen Lariviere, RPh, Kevin Miler, RPh, Eunice Lopez, CPhT 
BACKGROUND 
According to the Association of American Medical College, there is 
expected to be a physician shortage 121,300 physicians by 2030 in 
the US. Coupled with the current nursing shortage, it is becoming 
increasingly difficult for Primary Care to manage patients disease 
states effectively and provide access to care in a timely manner. 
About 157 million Americans (48% of the total U.S. population) live 
with a chronic condition. We established a clinical pharmacy 
presence within Baystate High Street Health Center – Adult 
Medicine (BHSHC-AM) to accommodate medication related needs 
of both patients and providers.  The Pharmacy Consult Clinic is 
available 3 days per week and assists in bridging the provider 
shortage gap.  By providing patients with access to our Pharmacy 
Consult Clinic, we have been able to show great benefits while 
obtaining positive outcomes of chronic disease states. 
 
 
The chart shows the percentage that each intervention is performed 
during a pharmacy consult visit. Along with addressing interventions 
we are able perform a complete medication reconciliation at all 
visits. The medication list in CIS is updated every time. 
 
By providing this teaching and education, our results demonstrated 
that we were successfully able to decrease each patient A1C by an 
average of 0.81% after just one pharmacy consult visit.  
METHODS 
PHARMACIST INTERVENTIONS RESULTS 
 
 
ENHANCED PHARMACY SERVICES 
UMMS-Baystate Research & Education:  Together we advance the state of caring through discovery & innovation 
DISCLOSURES 
      Authors of this presentation have nothing to disclose concerning possible financial 
or personal relationships with commercial entities that may have direct or indirect 
interest in the subject matter of this presentation. 
Patients  referred 
to Pharmacy 











• Identify gaps of therapy Addition of therapy 
• Identify inappropriate medications or medications no longer needed 
Discontinuation of 
therapy 
• Optimize therapy by decreasing pill burden with combination medications, 
determine appropriateness of dosage forms 
• Identify suboptimal or supratherapeutic dosing 
Dose change or change 
of medication 
• Diabetes, Hypertension, Asthma 
Chronic disease 
education 
• Recommend labs based on medication guidelines (A1C, liver function tests, lipid 
panel, TSH, etc.) 
Recommend laboratory 
testing 
• Demonstration of proper portion sizes and carbohydrate counting Nutrition education 
• Identify patients that need to be seen in clinic for an urgent visit Referred to provider 
• Assess readiness to quit, treatment options and continued support 
Smoking cessation 
education 
• Refill prescriptions per clinic protocol and obtain refills from provider 
Obtain prescription 
refills 
• Obtain patient history, identify duplicate prescriptions, determine adherence, and 
update CIS medication lists 
Medication 
Reconciliation 
Free prescription delivery service began in April 2018.  The number 
of prescriptions delivered continues to grow. 
 
To date, over 4000 prescriptions have been delivered and patient 
and provider satisfaction has been enhanced.  Due to this, 
prescription volume has increased in the pharmacy by 25%. 
 
 
• Diabetes: Insulin teaching, 
glucometer training, complications, 
and interpretation of glucose 
readings/A1C 
• Hypertension: complications, diet 
and exercise 
• Asthma: inhaler/spacer training, 
monitor use of rescue inhaler, 









































The TOC pharmacy resident plays a vital role in patient 
centered care & has led to improved outcomes such as: 
• Increased access to follow up care post hospital discharge 
• Increased medication adherence 




Transitions of Care: 
Longitudinal Pharmacy Resident Learning Experience 
 
Melanie Conboy PharmD1; Geena Eglin, PharmD1; Jennifer Glisson, PharmD1; 
 Jared Ostroff,  PharmD, BCACP1,2, BCGP 
1. Baystate Medical Center; 2. Western New England University CoPHS – Springfield, Massachusetts 
• The transitions of care (TOC)  pharmacy learning experience  was  newly 
re-designed to have the pharmacy resident complete  patient centered 
teaching and education surrounding the medication-use process . 
• Pharmacy involvement throughout TOC helps to improve patient 
outcomes, reduce readmissions, and benefit patients’ quality of life.  
       
Follow up with patients in their assigned outpatient clinics 
Identify language & literacy barriers and provide counseling for patients 
Work to resolve medication access issues prior to hospital discharge 
Provide resources for patients to obtain prescribed medication therapy  
Complete admission and discharge medication reconciliations  
Disclosures: The authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities. 
LEARNING OBJECTIVES 
DISCUSSION 
Baseline Characteristics (n = 45) 
 Average Age (±SD) 57.3 ± 16.3 
Male 22 (48.8) 
Average # of Home Medications 14.9 
Average # of Incorrect Medications* 5.79 
*Medications incorrect from home list; needed to be changed  
Total Population  n = 45 
Medication Access n = 17 (38%) 
Counseling & Education n = 41 (91%) 
Clinical Pharmacists Interventions n = 26 (58%) 
Medication Reconciliation n = 45 (100%) 




























Counseling & Education 
(n = 41)  
45 
17 14 14 14 
2 3 
9 







Hospital Readmission Rate Total
*New PO therapies; 
antibiotics; adverse events;  
disease state education; 
lifestyle modifications 
Inclusion Criteria 
• Admitted patients: 2 weeks prior to running the MIDAS report 
• Brightwood Health Center (BWHC) or High Street Health Center (HSHC) 
patients 
• Patients still admitted to the hospital; plans for discharge home 
Exclusion Criteria 
• Patients with planned discharge to a rehabilitation facility 
• Patients already discharged from the hospital 
RESULTS 
Hospital Readmission Rate 
Patients were followed 30 days past their hospital discharge date to evaluate 
the efficacy of post discharge pharmacy follow up.  
• HSHC follow up patients = 11.7% 
• BWHC follow up patients = 21.4% 
• Patients with no clinic follow up = 64.2% 
Financial Impact Future Directions 
Cost avoidance for medical readmission (~ $ 1,020.00/pt.) TOC services to all units 
Cost avoidance for cardiac readmission (~ $ 2,087.00/pt.) FTE approval for TOC Pharmacists 
TOC Pharmacist follow up = billable clinical services Code 99495 & Code 99496 utilization  
